郭艺伟,张翼,李花月,等.冷泉来源诺卡氏菌OUCLQ19-35-1次级代谢产物的研究[J].中国海洋药物,2022,41(4):12-18.
冷泉来源诺卡氏菌OUCLQ19-35-1次级代谢产物的研究
Studies on the secondary metabolites of cold seep-derived Nocardiopsis sp. OUCLQ19-35-1
投稿时间:2021-05-14  修订日期:2021-06-08
DOI:
中文关键词:  冷泉  诺卡氏菌  活性次级代谢产物  多重耐药菌
English Keywords:Cold seep  Nocardiopsis  Active secondary metabolites  Multi-drug resistant bacteria
Fund Project:
作者单位E-mail
郭艺伟 中国海洋大学医药学院 gyiweiyx@163.com 
张翼 中国海洋大学医药学院 mikez29@icloud.com 
李花月 中国海洋大学医药学院 lihuayue@ouc.edu.cn 
肖菲 中国海洋大学医药学院 xiaofei3450@ouc.edu.cn 
李文利* 中国海洋大学医药学院 liwenli@ouc.edu.cn 
摘要点击次数: 1937
全文下载次数: 2
中文摘要:
      目的 探究深海冷泉来源微生物的次级代谢产物产生能力,从中挖掘具有抗多重耐药(multi-drug resistant, MDR)菌活性的次级代谢产物,为新药研发提供化合物实体。方法 采用稀释涂布法分离纯化深海冷泉海泥样品中的放线菌,通过琼脂扩散法筛选具有抗MDR菌活性的放线菌;基于16S rRNA基因片段序列分析和系统进化树构建初步确定目标放线菌种属;对目标放线菌进行大规模发酵,采用有机溶剂萃取、反相硅胶柱层析、半制备高效液相等分离手段对发酵产物进行分离纯化,利用NMR、MS等波谱学技术并结合文献对化合物进行结构鉴定,然后对化合物进行抗MDR菌活性测试。结果 从深海冷泉中筛选到一株具有抗MDR菌Micrococcus luteus ML01和Staphylococcus aureus CCARM3090活性的放线菌OUCLQ19-35-1,16S rRNA序列及系统进化树分析初步确定其为Nocardiopsis synnemataformans;从其发酵产物中分离得到3个化合物,分别为questiomycin A(1)、1,6-dihydroxyphenazine(2)和5a,6,11a,12-tetrahydro-5a,11a-dimethyl[1,4]benzoxazino[3,2-b][1,4]benzoxazine(3);活性结果显示,化合物1-3均无抗MDR菌活性,但其所在的组分有抑菌活性。结论 从深海冷泉筛选得到一株诺卡氏菌OUCLQ19-35-1,其能够产生抗MDR菌的活性次级代谢产物,具有潜在的应用价值,但其活性成分待进一步的确定。
English Summary:
      Objective The purpose of this study was to explore the secondary metabolite production capacity of microorganisms from cold seep and to mine antibacterial secondary metabolites against development. Methods The cold seep actinomycetes were separated and purified using dilution plate method; the actinomycetes potentially producing antibacterial compounds were screened by agar diffusion method. Phylogenetic tree based on 16S rRNA sequences was constructed to primarily identify the strain species. The fermentation extract was separated by solvent extraction, reverse phase silica gel chromatography and semi-preparative HPLC. The compounds structures were identified by spectroscopic analysis (NMR and MS) as well as comparison with published researches, followed by anti-MDR activities tests. Results An actinomycetes strain OUCLQ19-35-1 showed good antibacterial activity against Micrococcus luteus ML01and Staphylococcus aureus CCARM3090 was obtained from cold seep. 16 S rRNA-based phylogenetic tree analysis showed that the strain belonged to Nocardiopsis synnemataformans. Three compounds were isolated from the fermentation broths of OUCLQ19-35-1 and their structures were identified as questiomycin A (1), 1,6-Dihydroxyphenazine (2) and 5a,6,11a,12-tetrahydro-5a,11a-dimethyl[1,4]benzoxazino[3,2-b][1,4]benzoxazine (3). While none of them showed activities against MDR bacteria, the fraction containing compound 1-3 as the major component exhibited good antibacterial activities. Conclusion OUCLQ19-35-1 was obtained from cold seep. The strain can produce bioactive secondary metabolites against MDR bacteria with potential application value, but the active ingredients need to be further determined.
查看全文  查看/发表评论  下载PDF阅读器
关闭